Kura Oncology (NASDAQ:KURA) Raised to "Strong-Buy" at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Kura Oncology (NASDAQ:KURA - Free Report) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Kura Oncology's FY2025 earnings at ($2.94) EPS.

Several other analysts also recently weighed in on the company. Bank of America decreased their price objective on Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a report on Friday, November 22nd. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Scotiabank dropped their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.50.

Remove Ads

Kura Oncology Trading Down 2.2 %

Shares of NASDAQ:KURA traded down $0.17 on Tuesday, hitting $7.53. 1,291,397 shares of the company's stock were exchanged, compared to its average volume of 1,591,525. The stock has a market capitalization of $608.09 million, a price-to-earnings ratio of -3.19 and a beta of 0.85. Kura Oncology has a 12 month low of $6.98 and a 12 month high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business's 50 day simple moving average is $8.00 and its two-hundred day simple moving average is $13.38.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its holdings in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after acquiring an additional 84,563 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Kura Oncology in the 4th quarter worth about $436,000. Moody Aldrich Partners LLC increased its stake in Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after buying an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after acquiring an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Kura Oncology in the fourth quarter valued at approximately $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.